Gilead Sciences' Next-Generation HIV Drug Hits the Mark

Gilead Sciences (GILD) got what it wanted and maybe more from the two Phase III studies of its next-generation HIV drug TAF.

I previewed the importance of TAF to GIlead as a superior replacement to its stalwart but patent-challenged HIV drug Viread on Monday. This morning, the company announced positive results with the TAF-containing regimen (Stribild-TAF) demonstrating statistical non-inferiority to Stribild on the primary endpoint of HIV viral load reduction. 

Better yet, TAF came out superior on two key safety endpoints measuring kidney function and bone mineral density compared to Viread. 

Based on the data from the two studies, Gilead intends to seek regulatory approval for TAF in the U.S. and Europe during the fourth quarter. 

Gilead shares were up about 1.5% to $106.95 in Wednesday trading. The stock's performance this year has been phenomenal, up 42% for the year to date and over 70% for the past 52 weeks.

GILD Chart

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

10 Key Takeaways From Google's Solid Earnings Report

10 Key Takeaways From Google's Solid Earnings Report

Amazon Is as Well-Positioned as Anyone to Create a Popular Home Robot

Amazon Is as Well-Positioned as Anyone to Create a Popular Home Robot

Bitcoin Today: Prices Flirt With $9,000 After Weekend Boom

Bitcoin Today: Prices Flirt With $9,000 After Weekend Boom

Tech Stocks Have You Baffled? Educate Yourself in Some Portfolio Diversification

Tech Stocks Have You Baffled? Educate Yourself in Some Portfolio Diversification

Halliburton Rises Slightly After Revenue Jump

Halliburton Rises Slightly After Revenue Jump